<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2934121</article-id><article-id pub-id-type="publisher-id">cc8714</article-id><article-id pub-id-type="doi">10.1186/cc8714</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Adding ultralow-dose oral naltrexone to morphine: a double-blind, randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Farahmand</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Ahmadi</surname><given-names>O</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib></contrib-group><aff id="I1"><label>1</label>Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="I2"><label>2</label>Esfahan University of Medical Sciences, Esfahan, Iran</aff><pub-date pub-type="ppub"><year>2010</year></pub-date><pub-date pub-type="epub"><day>1</day><month>3</month><year>2010</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">30th International Symposium on Intensive Care and Emergency Medicine</named-content><ext-link ext-link-type="uri" xlink:href="http://ccforum.com/supplements/notes/ccv14s1-info.pdf">http://ccforum.com/supplements/notes/ccv14s1-info.pdf</ext-link></supplement><fpage>P482</fpage><lpage>P482</lpage><permissions><copyright-statement>Copyright &#x000a9;2010 BioMed Central Ltd.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>BioMed Central Ltd.</copyright-holder></permissions><self-uri xlink:href="http://ccforum.com/content/14/S1/P482"/><conference><conf-date>9&#x02013;12 March 2010</conf-date><conf-name>30th International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>Ultralow-dose opioid antagonists can enhance opioid analgesia and prevent tolerance in rodent nociceptive pain assays.</p></sec><sec sec-type="methods"><title>Methods</title><p>A randomized, double-blind controlled trial is designed to investigate whether the addition of 5 ml ultralow-dose naltrexone (1 &#x003bc;g in a liter of sterile water) to morphine (0.05 mg/kg) changes the total opioid requirement and side effects.</p></sec><sec><title>Results</title><p>Two hundred and sixty-seven patients (18 to 45 years old) with moderate extremities trauma entered the study, Pain control measurements were evaluated every 15 minutes for the first hour, then every 30 minutes for the second and third hours and finally at the fourth hour. Efficacy was measured by the 11-point numerical pain rating scale. The following side effects were evaluated: sedation, nausea, vomiting and pruritus. We found that opioid requirements did not differ significantly between groups. The morphine + naltrexone group on average required 0.04 mg more morphine during the 4 hours than the morphine group.</p></sec><sec><title>Conclusions</title><p>The morphine + naltrexone group had a lower incidence of nausea than the morphine + placebo group. However, the incidence of vomiting, pruritus and sedation between the two groups were similar. The combination of ultralow-dose naltrexone and morphine in moderate extremities trauma did not affect opioid requirements, but it decreased the incidence of nausea.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Crain</surname><given-names>SM</given-names></name><name><surname>Shen</surname><given-names>KF</given-names></name><article-title>Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability</article-title><source>Pain</source><year>2000</year><volume>84</volume><fpage>121</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(99)00223-7</pub-id><pub-id pub-id-type="pmid">10666516</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Cepeda</surname><given-names>MS</given-names></name><name><surname>Africano</surname><given-names>JM</given-names></name><name><surname>Manrique</surname><given-names>AM</given-names></name><name><surname>Fragoso</surname><given-names>W</given-names></name><name><surname>Carr</surname><given-names>DB</given-names></name><article-title>The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period</article-title><source>Pain</source><year>2002</year><volume>96</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(01)00425-0</pub-id><pub-id pub-id-type="pmid">11932063</pub-id></mixed-citation></ref></ref-list></back></article>